



- The Report describes correctly the current situation in the EU in regard to HAMPs and shows an un-harmonised and fragmentised implementation of the present legal regulations.
- The consequences are described as well very correctly: **unequal availability** of HAMPs,
- and in this bracket especially the AMP, anthroposophic medicinal products



- The Netherlands.
- Anthroposophic doctors work as general practitioners inside the national health system.
- For 25 years about 1500 anthroposophic medicinal products available.
- With the present regulation only about 50 registrations are left.



Germany

- Anthroposophic medicine is strongly hospital based with university hospitals, general hospitals also with emergency first aid departments.
- In a pharmacy the patient can buy the full range of anthroposophic medicinal products without any problem.



 In other member states more or less the same situation: only a dozen or a hundred AMPs on the market available.

- For 25 years more than 1500 natural medicines on the market in EU
- Now un-harmonised and fragmentised implementation of the present legal regulations.



EC opinion on Matrix report:

- The study report was developed by an external contractor.
- It is a working document of the Pharmaceutical Committee
- Does not necessarily reflect the official opinion of the European Commission.



EC opinion on Matrix report:

- Generally no major issues regarding the availability of homeopathic and anthroposophic medicinal products for specific symptoms
- The availability of such products in all Member States is not particularly problematic, with the products surveyed generally being available when ordered in advance.



EC opinion on Matrix report:

- The Commission has no plans to modify the legislation on homeopathic medicinal products
- Or to introduce a specific framework for anthroposophic medicinal products.

EC ordering in advance from abroad

- Norway: Customs destroys AMP as not recognised as MP
- Not in all member states it is permitted to order from abroad.



Internationale Vereinigung Anthroposophischer Ärztegesellschaften International Federation of Anthroposophic Medical Associations Fédération Internationale des Associations Médicales Anthroposophiques

Anthroposophic Medicine (AM) in EU

- Widely used Integrative Medicine system in Europe since 1920
- Practised in 19 of the 27 Member States (Austria, Belgium, Czech
- Republic, Denmark, Eire, Estonia, Finland, France, Germany,
- Italy, Latvia, Netherlands, Poland, Portugal, Rumania, Spain,
- Sweden, United Kingdom) as well as in Norway and Switzerland
- 28 Hospitals in EU
- 15 AM Hospitals or AM departments in public hospitals in D + CH
- Size: 70 500 inpatients
- All specialisations in medicine
- Specialised medical departments









Internationale Vereinigung Anthroposophischer Ärztegesellschaften International Federation of Anthroposophic Medical Associations Fédération Internationale des Associations Médicales Anthroposophiques

Anthroposophic Medicine (AM) in EU

- Fully integrated into Healthcare Systems
- Acute >> chronic diseases
- Integrative medicine =
 - = Conventional and AM therapies(medicines and non-medical)
- Connected to unis / medical schools,
- Postgraduate medical training
- Chairs of AM at Universities
- Lectures on AM part of Uni teaching
- Several research institutes for AM or IM (integrative medicine)




CAM Interest Group EP 01072015 AMP



Internationale Vereinigung Anthroposophischer Ärztegesellschaften International Federation of Anthroposophic Medical Associations Fédération Internationale des Associations Médicales Anthroposophiques

Anthroposophic Medicine (AM)and therapies in EU



- EC: the availability of AMP is not a problem because medicines can be ordered in advance from abroad.
- This does not fit with the status of AM as integrated health care in the national health systems.
- AM doctors need AMP for their patients in hospitals for example for
 - Acute asthma attacks
 - Hypertensive crises (acute high blood pressure)
 - Acute allergic reactions
 - Acute pneumonia

Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2013, Article ID 578274, 16 pages http://dx.doi.org/10.1155/2013/578274



Research Article

Inpatient Treatment of Community-Acquired Pneumonias with Integrative Medicine

Ulrich Geyer, ¹ Klas Diederich, ^{1,2} Maria Kusserow, ¹ Andreas Laubersheimer, ¹ and Klaus Kramer³

Correspondence should be addressed to Ulrich Geyer; geyerul@googlemail.com

Received 30 August 2012; Revised 7 February 2013; Accepted 7 March 2013

¹ Department of Homeotherapy, Heidenheim Hospital, Teaching Hospital of The University of Ulm, Schloßhaustraße 100, 89522 Heidenheim, Germany

² Departement of Mathematics, University of Wuppertal, 42119 Wuppertal, Germany

³ Departement of CI, University of Ulm, 89081 Ulm, Germany

- AM GPs need AMP for emergency and acute situations for example for:
 - Acute asthma attack
 - Circulation collaps
 - Acute migraine
 - Acute urinary tract infection
 - Acute upper respiratory tract infections
 - Acute pneumonia

Best practice of treatments without antibiotics that contributes to combatting AMR.

• Treating infections with AMPs supports EU policy against AMR.



Anthroposophic Medicinal Products (AMP) can be registered as homeopathic and others as herbal MP, but the most typical and widely used AMP cannot be authorised either as HMP or as herbal medicines.



- So we fully underline the conclusion of the Matrix report that
- the existing legislation may fall short of simplifying procedures...
- there is no clear and consistent EU registration procedures for HAMPs not covered by Art 14 (1) DR 2001/83.
- the implementation of existing EU provision concerning these products (HAMPs) could be further improved...(p 111).
- and the availability of anthroposophical medicinal products is still worse than the situation of the homeopathic medicinal products.

 The Matrix Insight Report findings offer a good starting point for new approach to deal with these considerations of the EU Commission and with the drivers of the availability problems for medicinal products, especially in the field of the HAMPs.



 Their availability is fragmented to a surprisingly high degree in the different markets of these countries, which has, again, definite negative repercussions for the application of the AM therapeutic system for patients and practitioners as well as for the AM as an accepted and patientdemanded part of CAM and Integrative Medicine.



Thank you for your attention